Statistiche di base
| LEI | 549300FGLYJVWKVH3W38 |
| CIK | 1292519 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to InVivo Therapeutics Holdings Corp.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| February 14, 2024 |
US46186M6057 / INVIVO THERAPEUTICS HLDNG CORP / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.00001 per share, of InVivo Therapeutics Holdings Corp. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an ex |
|
| February 13, 2024 |
US46186M6057 / INVIVO THERAPEUTICS HLDNG CORP / Lind Global Fund II LP Passive Investment SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* InVivo Therapeutics Holdings Corp. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 46186M605 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check t |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employ |
|
| February 6, 2024 |
NVIV / InVivo Therapeutics Holdings Corp. / Foose Brice - BRICE FOOSE Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* INVIVO THERAPEUTICS HOLDINGS CORP. (Name of Issuer) Common Stock (Title of Class of Securities) 46186M506 (CUSIP Number) February 05, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employ |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 29, 2023 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employ |
|
| December 5, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2023 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other Jurisdiction (Commission (IRS Employ |
|
| November 30, 2023 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 30, 2023 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employ |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 21, 2023 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employ |
|
| November 8, 2023 |
LEASE TERMINATION AND SETTLEMENT AGREEMENT Exhibit 10.1 EXECUTION LEASE TERMINATION AND SETTLEMENT AGREEMENT This lease termination and settlement agreement (the “Settlement Agreement”) dated as of August 29, 2023 (the “Settlement Effective Date”), is entered into by and between InVivo Therapeutics Corporation (“InVivo”), and ARE-MA Region No. 59, LLC (“ARE,” and together with InVivo, the “Parties”), with reference to the following: RECITA |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 29, 2023 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employer |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| April 25, 2023 |
NVIV / InVivo Therapeutics Holdings Corp / Foose Brice - BRICE FOOSE Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INVIVO THERAPEUTICS HOLDINGS CORP. (Name of Issuer) Common Stock (Title of Class of Securities) 46186M506 (CUSIP Number) April 20, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 9, 2023 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employer J |
|
| March 9, 2023 |
Exhibit 99.1 InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury Study did not achieve primary endpoint of defined improvement on standard impairment scale InVivo to evaluate full data set and strategic options for the company CAMBRIDGE, Mass – March 9, 2023 – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomater |
|
| March 1, 2023 |
Description of the Registrant’s Securities. Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of registered securities of InVivo Therapeutics Holdings Corp. (“us,” “our,” “we” or the “Company”) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our articles of incorporation, as amended, our |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-37350 INVIVO THER |
|
| February 14, 2023 |
US46186M6057 / INVIVO THERAPEUTICS HLDNG CORP / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-nviv123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* InVivo Therapeutics Holdings Corp. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 46186M605 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement |
|
| February 13, 2023 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common stock, par value $0.00001 per share, of InVivo Therapeutics Holdings Corp. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an ex |
|
| February 13, 2023 |
SC 13G/A 1 sc13ga.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* InVivo Therapeutics Holdings Corp. (Name of Issuer) Common stock, par value $0.00001 per share. (Title of Class of Securities) 46186M605 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this S |
|
| November 21, 2022 |
InVivo Therapeutics Holdings Corp. 3,016,191 Shares of Common Stock TABLE OF CONTENTS ? Filed pursuant to Rule 424(b)(3)? ?Registration No. 333-268256? Prospectus InVivo Therapeutics Holdings Corp. 3,016,191 Shares of Common Stock This prospectus relates to the resale by the selling stockholders identified in this prospectus of up to (i) up to an aggregate of 1,190,476 shares of our common stock that are issuable upon the exercise of certain outstanding warrants, |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 17, 2022 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employ |
|
| November 18, 2022 |
Exhibit 10.1 Amendment to the Employment Agreement This Amendment to the Employment Agreement (the “Amendment”) is entered into by and between InVivo Therapeutics Holdings Corp. (the “Company”) and Richard Christopher (the “Executive”) and shall become effective as of November 17, 2022 (the “Effective Date”). WHEREAS, the Company and Executive are parties to an Employment Agreement dated December |
|
| November 17, 2022 |
CORRESP 1 filename1.htm InVivo Therapeutics Holdings Corp. One Kendall Square, Suite B14402 Cambridge, MA 02139 November 17, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: InVivo Therapeutics Holdings Corp. Registration Statement on Form S-1 File No. 333-268256 Request for Acceleration Ladies and Gentlemen: Pursuant t |
|
| November 9, 2022 |
As filed with the Securities and Exchange Commission on November 8, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 8, 2022 Registration No. |
|
| November 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Invivo Therapeutics Holdings Corp. |
|
| November 7, 2022 |
As filed with the Securities and Exchange Commission on November 7, 2022 As filed with the Securities and Exchange Commission on November 7, 2022 Registration No. |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended September 30, 2022 ? or ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to . |
|
| November 7, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Invivo Therapeutics Holdings Corp. |
|
| November 7, 2022 |
Exhibit 10.1 ? EMPLOYMENT AGREEMENT ? This EMPLOYMENT AGREEMENT (the ?Agreement?) is made between InVivo Therapeutics Holdings Corp. (the ?Company?) a corporation duly organized and validly existing under the laws of the State of Nevada having a business address of One Kendall Square, Building 1400 West, Floor 4, Cambridge, MA 02139, and Heather Hamel (the ?Executive?). ? WITNESSETH THAT: ? WHEREA |
|
| October 11, 2022 |
Form of Unregistered Pre-Funded Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 11, 2022 |
154,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 369,810 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-234353 Prospectus Supplement (To Prospectus Dated November 14, 2019) 154,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 369,810 Shares of Common Stock We are offering (i) 154,000 shares of our common stock and (ii) pre-funded warrants to purchase up to 369,810 shares of common stock to an institutional inve |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2022 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other Jurisdiction (Commission (IRS Employe |
|
| October 11, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October 7, 2022, between InVivo Therapeutics Holdings Corp., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and |
|
| October 11, 2022 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of October 7, 2022, between InVivo Therapeutics Holdings Corp., a Nevada corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and |
|
| October 11, 2022 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of October 7, 2022, between InVivo Therapeutics Holdings Corp., a Nevada corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securiti |
|
| October 11, 2022 |
Form of Registered Pre-Funded Warrant Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT InVivo Therapeutics Holdings Corp. Warrant Shares: Issue Date:, 2022 Initial Exercise Date: , 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| October 11, 2022 |
19,048 Shares of Common Stock Issuable Upon the Exercise of Warrants Filed pursuant to Rule 424(b)(3) Registration No. 333-238635 Prospectus Supplement (To the Prospectus dated June 4, 2020) 19,048 Shares of Common Stock Issuable Upon the Exercise of Warrants This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated June 4, 2020 (the ?Original Prospectus?), relating to the resale by a selling stockholder named t |
|
| October 11, 2022 |
Form of Preferred Investment Option Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 11, 2022 |
Form of Placement Agent Preferred Investment Option Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 11, 2022 |
Exhibit 99.1 InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules CAMBRIDGE, Mass.-(BUSINESS WIRE)- InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has entered into a def |
|
| September 13, 2022 |
Exhibit 3.2 Filed in the Office of Secretary of State State Of Nevada Business Number C7829-2003 Filing Number 20222608445 Filed On 9/12/2022 12:20:00 PM Number of Pages 3 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Profit Corporation: ~(~v);, t-1 Certificate of Amendment Certificate to Accompany Restated Artic |
|
| September 13, 2022 |
Exhibit 3.1 Filed in the Office of Secretary of State State Of Nevada Business Number C7829-2003 Filing Number 20222607991 Filed On 9/12/2022 10:44:00 AM Number of Pages 3 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Profit Corporation: Certificate of Amendment (PuRsuANTro NRs 78 . 380 & 78 . 385/78 . 390) Certi |
|
| September 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 9, 2022 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employ |
|
| September 6, 2022 |
DEFA14A 1 tm2225125d1defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as |
|
| August 18, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rul |
|
| August 18, 2022 |
One Kendall Square, Suite B14402 Cambridge, MA 02139 CORRESP 1 filename1.htm One Kendall Square, Suite B14402 Cambridge, MA 02139 August 18, 2022 VIA ELECTRONIC SUBMISSION Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: InVivo Therapeutics Holdings Corp. Commission File No. 001-37350 Definitive Proxy Materials Ladies and Gentlemen: On behalf of InVivo Therapeutics Holdings Corp. (the “Company”), transmitted herewith |
|
| August 11, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rul |
|
| August 11, 2022 |
August 11, 2022 By Electronic Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Schwartz and Celeste Murphy Re: InVivo Therapeutics Holdings Corp. Revised Preliminary Proxy Statement on Schedule 14A Filed July 25, 2022 File No. 001-37350 Ladies and Gentlemen: InVivo Therapeutics H |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2022 ? or ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to . |
|
| July 25, 2022 |
July 25, 2022 By Electronic Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Schwartz Celeste Murphy Re: InVivo Therapeutics Holdings Corp. Preliminary Proxy Statement on Schedule 14A Filed July 8, 2022 File No. 001-37350 Ladies and Gentlemen: InVivo Therapeutics Holdings Corp. ( |
|
| July 25, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by R |
|
| July 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 7, 2022 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employer Ju |
|
| July 12, 2022 |
Exhibit 10.1 InVivo Therapeutics Holding Corp. Transaction Incentive Plan This Transaction Incentive Plan is established by InVivo Therapeutics Holding Corp., a Nevada corporation (the ?Company?), effective as of August 11, 2021 (the ?Effective Date?), and as amended on July 7, 2022. 1. Purpose. The purpose of this Plan is to retain and motivate members of management and other employees of the Com |
|
| July 8, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rul |
|
| June 2, 2022 |
Exhibit 99.1 InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study Topline data expected to be reported in Q1 2023 CAMBRIDGE, Mass ? June 2, 2022 ? InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it h |
|
| June 2, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 2, 2022 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employer Ju |
|
| May 26, 2022 |
One Kendall Square, Suite B14402 Cambridge, MA 02139 Exhibit 99.1 One Kendall Square, Suite B14402 Cambridge, MA 02139 May 26, 2022 NOTICE OF VOTING RIGHTS Dear InVivo Stockholder: Notice is hereby given as to the adoption by the Board of Directors of InVivo Therapeutics Holdings Corp., a Nevada corporation, of the Voting Rights Plan attached hereto as Appendix A. The Voting Rights Plan is of limited scope of and purpose and is designed to facilitat |
|
| May 26, 2022 |
Voting Rights Plan, dated as of May 26, 2022 Exhibit 4.1 INVIVO THERAPEUTICS HOLDINGS CORP. VOTING RIGHTS PLAN This Voting Rights Plan (this ?Plan?) is made and adopted by the Board of Directors (the ?Board?) of InVivo Therapeutics Holdings Corp., a Nevada corporation (the ?Corporation?), as of May 26, 2022 (the ?Effective Date?), and, to the extent eligibility is established, by each Eligible Stockholder (as defined herein). WHEREAS, the Bo |
|
| May 26, 2022 |
Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 26, 2022 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employer Ju |
|
| May 26, 2022 |
Exhibit 99.2 The undersigned is the owner of a minimum of 50 shares of common stock, $0.00001 par value (?Common Stock?), of InVivo Therapeutics Holdings Corp., a Nevada corporation (?InVivo?), and hereby confirms eligibility for the additional voting rights set forth in the Voting Rights Plan, as adopted by the InVivo Board of Directors on May 26, 2022 (capitalized terms used herein and not defin |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2022 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employer Ju |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended March 31, 2022 ? or ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to . |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 26, 2022 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employer |
|
| April 26, 2022 |
Exhibit 3.1 Filed in the Office of Secretary of State State Of Nevada Business Number C7829-2003 Filing Number 20222273119 Filed On 4/25/2022 10:14:00 AM Number of Pages 1 |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2022 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other Jurisdiction (Commission (IRS Employer |
|
| March 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 11, 2022 |
SC 13G/A 1 ea155271-13ga2intrainvivo.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* InVivo Therapeutics Holdings Corp. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 46186M506 (CUSIP Number) December 31, 2021 (Date of Eve |
|
| February 9, 2022 |
NVIV / Invivo Therapeutics Holdings Corp / Lind Global Macro Fund LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* InVivo Therapeutics Holdings Corp. (Name of Issuer) Common stock, par value $0.00001 per share. (Title of Class of Securities) 46186M506 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| November 29, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2021 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other Jurisdiction (Commission (IRS Emplo |
|
| November 29, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this ?First Amendment?) is made as of November 23, 2021, by and between ARE-MA REGION NO. 59, LLC, a Delaware limited liability company (?Landlord?), and INVIVO THERAPEUTICS CORPORATION, a Delaware corporation (?Tenant?). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated as of May 28, 2021 (the |
|
| November 16, 2021 |
Form S-8, File No. 333-261117 , filed with the Securities and Exchange Commission November 16, 2021 As filed with the Securities and Exchange Commission on November 16, 2021 Registration No. |
|
| November 16, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other Jurisdiction (Commission File Numbe |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended September 30, 2021 ? or ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to . |
|
| August 13, 2021 |
Exhibit 10.3 InVivo Therapeutics Holding Corp. Transaction Incentive Plan This Transaction Incentive Plan is established by InVivo Therapeutics Holding Corp., a Nevada corporation (the ?Company?), effective as of August 11, 2021 (the ?Effective Date?). 1.Purpose. The purpose of this Plan is to retain and motivate members of management and other employees of the Company by providing a meaningful fi |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended June 30, 2021 ? or ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to . |
|
| July 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 16, 2021 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employer J |
|
| July 9, 2021 |
DEFA14A 1 tm2121735d1defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: |
|
| July 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| July 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 1, 2021 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employer Ju |
|
| June 1, 2021 |
Exhibit 10.1 LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made as of this 28th day of May, 2021, between ARE-MA REGION NO. 59, LLC, a Delaware limited liability company (?Landlord?), and INVIVO THERAPEUTICS CORPORATION, a Delaware corporation (?Tenant?). BASIC LEASE PROVISIONS Address of Building: 1400 One Kendall Square, Cambridge, MA 02139 Premises: That portion of (i) the fourth floor |
|
| May 21, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 18, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 10, 2021 |
Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the quarterly period ended March 31, 2021 ? or ? ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to . |
|
| May 7, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 5, 2021 |
As filed with the Securities and Exchange Commission on March 5, 2021 Registration No. |
|
| March 1, 2021 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 1, 2021 |
Description of the Registrant’s Securities. Exhibit 4.1 ? DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of registered securities of InVivo Therapeutics Holdings Corp. (?us,? ?our,? ?we? or the ?Company?) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our articles of incorporation, as amended, ou |
|
| February 16, 2021 |
CUSIP No: 46186M506 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* InVivo Therapeutics Holdings Corp. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 46186M50 |
|
| February 9, 2021 |
SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 InVivo Therapeutics Holdings Corp. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 46186M506 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 InVivo Therapeutics Holdings Corp. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 46186M506 (C |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 1, 2021 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employe |
|
| January 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* InVivo Therapeutics Holdings Corp. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 46186M506 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| January 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* InVivo Therapeutics Holdings Corp. (Name of Issuer) Common stock, par value $0.00001 per share. (Title of Class of Securities) 46186M506 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| December 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2020 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| November 6, 2020 |
Form S-8, File No. 333-249928, filed with the Securities and Exchange Commission on November 6, 2020 As filed with the Securities and Exchange Commission on November 6, 2020 Registration No. |
|
| November 2, 2020 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated November 2,2020 with respect to the shares of Common Stock of InVivo Therapeutics Holdings Corp., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k |
|
| November 2, 2020 |
NVIV / InVivo Therapeutics Holdings Corp / BIGGER CAPITAL FUND L P Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| November 2, 2020 |
SC13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 InVivo Therapeutics Holdings Corp. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 46186M506 (CUSIP Number) October 22, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| October 26, 2020 |
Financial Statements and Exhibits 8-K 1 tm2032415-78k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 22, 2020 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Com |
|
| October 26, 2020 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-249353 Prospectus InVivo Therapeutics Holdings Corp. 11,785,000 Shares of Common Stock and Warrants to Purchase 11,785,000 Shares of Common Stock and Pre-funded Warrants to Purchase 6,965,000 Shares of Common Stock and Warrants to Purchase 6,965,000 Shares of Common Stock We are offering 11,785,000 shares of common stock, t |
|
| October 23, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common stock, par value $0.00001, of InVivo Therapeutics Holdings Corp. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. October 23, 2020 LIND GLOBAL MACRO FUND, LP By: Lind Global Partne |
|
| October 23, 2020 |
NVIV / InVivo Therapeutics Holdings Corp / Lind Global Macro Fund LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* InVivo Therapeutics Holdings Corp. (Name of Issuer) Common stock, par value $0.00001 per share. (Title of Class of Securities) 46186M506 (CUSIP Number) October 22, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to d |
|
| October 20, 2020 |
InVivo Therapeutics Holdings Corp. One Kendall Square, Suite B14402 Cambridge, MA 02139 October 20, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: InVivo Therapeutics Holdings Corp. Registration Statement on Form S-1 File No. 333-249353 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated un |
|
| October 16, 2020 |
Exhibit 4.14 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT InVivo Therapeutics Holdings Corp. Warrant Shares: Initial Exercise Date: , 20 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on o |
|
| October 16, 2020 |
Exhibit 4.13 SERIES B PRE-FUNDED COMMON STOCK PURCHASE WARRANT InVivo Therapeutics Holdings Corp. Warrant Shares: Initial Exercise Date: , 2020 THIS SERIES B PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| October 16, 2020 |
EX-4.12 2 tm2032415d4ex4-12.htm EXHIBIT 4.12 Exhibit 4.12 SERIES A COMMON STOCK PURCHASE WARRANT InVivo Therapeutics Holdings Corp. Warrant Shares: Initial Exercise Date: , 2020 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions herein |
|
| October 16, 2020 |
Form of Securities Purchase Agreement. EX-10.24 6 tm2032415d4ex10-24.htm EXHIBIT 10.24 Exhibit 10.24 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2020, between InVivo Therapeutics Holdings Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchase |
|
| October 16, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 16, 2020 Registration No. |
|
| October 7, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 6, 2020 Registration No. |
|
| August 11, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| August 5, 2020 |
Exhibit 3.1 ATTACHMENT TO CERTIFICATE OF AMENDMENT TO ARTICLES OF INCORPORATION OF INVIVO THERAPEUTICS HOLDINGS CORP. ENTITY NUMBER C7829-2003 The Articles of Incorporation of InVivo Therapeutics Holdings Corp., a Ne "Corporation"), as filed with the Nevada Secretary of State on April 2, 2003, to time, shall be and hereby is amended as follows: RESOLVED, that Article FOURTH of the Corporation 's A |
|
| August 5, 2020 |
INVIVO THERAPEUTICS HOLDINGS CORP. 2015 EQUITY INCENTIVE PLAN Exhibit 99.1 INVIVO THERAPEUTICS HOLDINGS CORP. 2015 EQUITY INCENTIVE PLAN C-1 INVIVO THERAPEUTICS HOLDINGS CORP. 2015 EQUITY INCENTIVE PLAN 1. Purpose C-3 2. Definitions C-3 3. Administration. C-6 4. Shares Subject to Plan. C-7 5. Eligibility; Per-Participant Limitations C-8 6. Specific Terms of Awards. C-8 7. Certain Provisions Applicable to Awards. C-12 8. Code Section 162(m) Provisions. C-14 9 |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 4, 2020 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employer |
|
| June 22, 2020 |
DEF 14A 1 tmb-20200804xdef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of th |
|
| June 9, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| June 5, 2020 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF INVIVO THERAPEUTICS HOLDINGS CORP., a Nevada Corporation (March 29, 2016) ARTICLE I OFFICES Section 1. Principal Office and Registered Agent. The principal office of the Corporation and the registered agent of the Corporation shall be as the Board of Directors may from time to time determine or the business of the Corporation may require. Section 2. Other |
|
| June 5, 2020 |
Exhibit 3.1 AMENDMENT TO BYLAWS OF INVIVO THERAPEUTICS HOLDINGS CORP. (as approved by the Company’s Board of Directors on June 5, 2020) Section 2 of the Bylaws is hereby amended and restated its entirety as follows: “Section 2. Quorum: Action by Vote: Adjournment of Meeting. Unless otherwise required by law or provided in the Articles of Incorporation or these Bylaws, the holders of one-third of t |
|
| June 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 5, 2020 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employer Ju |
|
| June 4, 2020 |
InVivo Therapeutics Holdings Corp. 1,826,731 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-238635 Prospectus InVivo Therapeutics Holdings Corp. 1,826,731 Shares of Common Stock This prospectus relates to the resale by the selling stockholders identified in this prospectus of up to 1,826,731 shares of our common stock that are issuable upon the exercise of certain outstanding warrants, or the warrants, to purchase sh |
|
| June 2, 2020 |
InVivo Therapeutics Holdings Corp. One Kendall Square, Suite B14402 Cambridge, MA 02139 June 2, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: InVivo Therapeutics Holdings Corp. Registration Statement on Form S-1 File No. 333-238635 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under |
|
| May 22, 2020 |
Table of Contents As filed with the Securities and Exchange Commission on May 22, 2020 Registration No. |
|
| May 13, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| April 24, 2020 |
46186M506 / INVIVO THERAPEUTICS HLDNG CORP / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 24, 2020 |
46186M506 / INVIVO THERAPEUTICS HLDNG CORP / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 46186M506 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* InVivo Therapeutics Holdings Corp. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 46186M506 |
|
| April 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* InVivo Therapeutics Holdings Corp. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 46186M506 (CUSIP Number) April 15, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| April 17, 2020 |
1,715,240 Shares of Common Stock Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| April 16, 2020 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 16, 2020 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 16, 2020 |
Exhibit 99.1 InVivo Therapeutics Announces $3.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules CAMBRIDGE, Mass. (April 15, 2020) — InVivo Therapeutics Holdings Corp. (NVIV) today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 1,715,240 shares of its common stock at a purchase price of $1.75 per |
|
| April 16, 2020 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 15, 2020, between InVivo Therapeutics Holdings Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and c |
|
| April 16, 2020 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 16, 2020 |
NVIV / InVivo Therapeutics Holdings Corp / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 11, 2020 |
Exhibit 4.2 FORM OF SERIES B PRE-FUNDED COMMON STOCK PURCHASE WARRANT INVIVO THERAPEUTICS HOLDINGS CORP. Warrant Shares: Initial Exercise Date: , 2020 THIS SERIES B PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| March 11, 2020 |
Financial Statements and Exhibits, Other Events QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 11, 2020 |
Exhibit 99.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2020, between InVivo Therapeutics Holdings Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition |
|
| March 11, 2020 |
Exhibit 4.1 FORM OF SERIES A COMMON STOCK PURCHASE WARRANT INVIVO THERAPEUTICS HOLDINGS CORP. Warrant Shares: Initial Exercise Date: , 20 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after |
|
| March 11, 2020 |
Exhibit 4.3 FORM OF PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT INVIVO THERAPEUTICS HOLDINGS CORP. Warrant Shares: Initial Exercise Date: , 20 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any ti |
|
| March 9, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(4) Registration Statement No. |
|
| March 5, 2020 |
Exhibit 4.10 FORM OF SERIES A COMMON STOCK PURCHASE WARRANT INVIVO THERAPEUTICS HOLDINGS CORP. Warrant Shares: Initial Exercise Date: , 20 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| March 5, 2020 |
NVIV / InVivo Therapeutics Holdings Corp S-1/A - - S-1/A QuickLinks - Click here to rapidly navigate through this document As filed with the Securities and Exchange Commission on March 4, 2020 Registration No. |
|
| March 5, 2020 |
Form of Series B Pre-Funded Warrant. Exhibit 4.11 FORM OF SERIES B PRE-FUNDED COMMON STOCK PURCHASE WARRANT INVIVO THERAPEUTICS HOLDINGS CORP. Warrant Shares: Initial Exercise Date: , 2020 THIS SERIES B PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth |
|
| March 5, 2020 |
Form of Placement Agent Warrant. Exhibit 4.12 FORM OF PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT INVIVO THERAPEUTICS HOLDINGS CORP. Warrant Shares: Initial Exercise Date: , 20 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any t |
|
| March 5, 2020 |
Form of Securities Purchase Agreement. Exhibit 10.26 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2020, between InVivo Therapeutics Holdings Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio |
|
| March 3, 2020 |
NVIV / InVivo Therapeutics Holdings Corp CORRESP - - InVivo Therapeutics Holdings Corp. One Kendall Square, Suite B14402 Cambridge, MA 02139 March 3, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: InVivo Therapeutics Holdings Corp. Registration Statement on Form S-1 File No. 333-236572 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under |
|
| March 2, 2020 |
NVIV / InVivo Therapeutics Holdings Corp S-1/A - - S-1/A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on March 2, 2020 Registration No. |
|
| March 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 28, 2020 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employ |
|
| February 24, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 21, 2020 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Emplo |
|
| February 21, 2020 |
As filed with the Securities and Exchange Commission on February 21, 2020 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on February 21, 2020 Registration No. |
|
| February 20, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001‑37350 INVIVO THER |
|
| February 20, 2020 |
As filed with the Securities and Exchange Commission on February 20, 2020 Registration No. |
|
| February 20, 2020 |
Description of the Registrant’s Securities. Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of registered securities of InVivo Therapeutics Holdings Corp. (“us,” “our,” “we” or the “Company”) is intended as a summary only and therefore is not a complete description. This description is based upon, and is qualified by reference to, our articles of incorporation, as amended, our |
|
| February 20, 2020 |
Exhibit 10.25 INVIVO THERAPEUTICS HOLDINGS CORP. RESTRICTED STOCK UNIT AGREEMENT InVivo Therapeutics Holdings Corp. (the “Company”) hereby grants the following restricted stock units pursuant to its 2015 Equity Incentive Plan and subject to the terms and conditions attached hereto and incorporated herein by reference. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of Res |
|
| February 20, 2020 |
Exhibit 10.15 INVIVO THERAPEUTICS HOLDINGS CORP. 2015 EQUITY INCENTIVE PLAN INVIVO THERAPEUTICS HOLDINGS CORP. 2015 EQUITY INCENTIVE PLAN 1. Purpose 3 2. Definitions 3 3. Administration. 7 4. Shares Subject to Plan. 8 5. Eligibility; Per-Participant Limitations 9 6. Specific Terms of Awards. 9 7. Certain Provisions Applicable to Awards. 15 8. Code Section 162(m) Provisions. 17 9. Change in Control |
|
| February 20, 2020 |
Exhibit 4.2 NE VADA SEAL CORPORATE InVivo Therapeutics Holdings Corp. TRANSFER AGENT AND REGISTRAR AUTHORIZED OFFICER CONTINENTAL STOCK TRANSFER & TRUST COMPANY (New York, NY) COUNTERSIGNED AND REGISTERED: BY: CHIEF EXECUTIVE OFFICER transferable on the books of the Corporation by the holder hereof in person or by duly authorized attorney upon surrender of this certificate properly endorsed. This |
|
| February 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 11, 2020 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employ |
|
| February 11, 2020 |
Exhibit 3.1 Filed in the Office of Business Number . J1. C7829-2003 K.f.A. F il in g N um be-r , 0 20200472678 Filed On Secretary of State 2/10/2020 10:44:00 AM S tate Of Nevada Number of Pages 1 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate of Change Pursuant to NRS 78.209 TYPE OR PRINT ·USE DARK INK |
|
| February 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2020 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 24, 2020 |
8-K 1 tm205676d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 21, 2020 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Comm |
|
| January 24, 2020 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 24, 2020 |
Exhibit 3.1 Filed in the Office of Secretary of State State Of Nevada Business Number 1 C7829-2003 Filing Number 20200430802 Filed On 1/21/2020 3:01:00 PM Number of Pages 3 1 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Profit Corporation: Certificate of Amendment (PURSUANT TO NRS 78.380 & 78.385/78.390) Certifi |
|
| January 16, 2020 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2020 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 10, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2019 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other Jurisdiction of |
|
| November 27, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| November 22, 2019 |
7,000,000 Shares of Common Stock Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| November 22, 2019 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT November 21, 2019 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), InVivo Therapeutics Holdings Corp., a Nevada corporation (the “Company”), hereby agrees to sell up to an aggregate of $840,000 of registered securities of the Company, includin |
|
| November 22, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2019 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 22, 2019 |
PUBLIC OFFERING SUBSCRIPTON AGREEMENT Exhibit 99.1 PUBLIC OFFERING SUBSCRIPTON AGREEMENT This agreement is dated November , 2019 between InVivo Therapeutics Holdings Corp., a Nevada corporation (the “Company”) and the undersigned subscriber (the “Subscriber”), whereby the parties agree as follows: The Subscriber shall buy and the Company agrees to sell the number of shares (the “Shares”) of Company’s common stock, $0.00001 par value p |
|
| November 21, 2019 |
INVIVO THERAPEUTICS HOLDINGS CORP. 7,586,711 Warrants to purchase shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-224424 and 333-225768 PROSPECTUS SUPPLEMENT NO. 9 (TO PROSPECTUS DATED JUNE 20, 2018, AS AMENDED JUNE 28, 2019) INVIVO THERAPEUTICS HOLDINGS CORP. 7,586,711 Warrants to purchase shares of Common Stock This prospectus supplement No. 9 supplements and amends the prospectus dated June 20, 2018, as amended June 28, 2019, and as supplemented by pro |
|
| November 21, 2019 |
Exhibit 10.2 SERIES A COMMON STOCK PURCHASE WARRANT INVIVO THERAPEUTICS HOLDINGS CORP. Warrant Shares: 7,621,211 Initial Exercise Date: June 25, 2018 CUSIP: 46186M 126 ISIN: US46186M1264 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and t |
|
| November 21, 2019 |
Exhibit 10.1 Second Amendment to Warrant Agency Agreement and Warrant This Amendment, dated November 20, 2019 (“Amendment”), is entered into by and between InVivo Therapeutics Holdings Corp., a Nevada corporation (the “Company”), and Continental Stock Transfer & Trust Company as Warrant Agent (the “Warrant Agent”), and amends that certain Warrant Agency Agreement, dated as of June 25, 2018, as ame |
|
| November 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2019 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 21, 2019 |
INVIVO THERAPEUTICS HOLDINGS CORP. 7,586,711 Warrants to purchase shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-224424 and 333-225768 PROSPECTUS SUPPLEMENT NO. 9 (TO PROSPECTUS DATED JUNE 20, 2018, AS AMENDED JUNE 28, 2019) INVIVO THERAPEUTICS HOLDINGS CORP. 7,586,711 Warrants to purchase shares of Common Stock This prospectus supplement No. 9 supplements and amends the prospectus dated June 20, 2018, as amended June 28, 2019, and as supplemented by pro |
|
| November 18, 2019 |
SUBJECT TO COMPLETION, DATED NOVEMBER 18, 2019 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| November 13, 2019 |
NVIV / InVivo Therapeutics Holdings Corp CORRESP - - INVIVO THERAPEUTICS HOLDINGS CORP. One Kendall Square Suite B14402 Cambridge, Massachusetts 02139 November 13, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: InVivo Therapeutics Holdings Corp. Registration Statement on Form S-3 File No. 333-234353 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 pro |
|
| November 12, 2019 |
Table of Contents As filed with the Securities and Exchange Commission on November 12, 2019 Registration No. |
|
| November 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2019 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 8, 2019 |
NVIV / InVivo Therapeutics Holdings Corp PRE 14A - - PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| November 7, 2019 |
Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| October 28, 2019 |
NVIV / InVivo Therapeutics Holdings Corp S-3 - - S-3 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on October 28, 2019. |
|
| September 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2019 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001‑37350 36‑4528166 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 27, 2019 |
Exhibit 10.1 INVIVO THERAPEUTICS HOLDINGS CORP. RESTRICTED STOCK AGREEMENT 2015 Equity Incentive Plan This Restricted Stock Agreement (this “Agreement”) is made as of the Grant Date set forth below between InVivo Therapeutics Holdings Corp., a Nevada corporation (the “Company”), and the Participant named below. NOTICE OF GRANT Name of Participant (the “Participant”): Grant Date: Number of shares o |
|
| September 11, 2019 |
NVIV / InVivo Therapeutics Holdings Corp CORRESP - - September 11, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Electronics and Machinery 100 F Street, NE Washington, D. |
|
| August 13, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| July 19, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2019 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 12, 2019 |
NVIV / InVivo Therapeutics Holdings Corp DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| July 12, 2019 |
InVivo Therapeutics Announces Postponement of Annual Meeting Exhibit 99.1 InVivo Therapeutics Announces Postponement of Annual Meeting CAMBRIDGE, Mass. (July 12, 2019) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that it has postponed its 2019 annual meeting of stockholders. The annual meeting, which was originally scheduled for June 11, 2019, had been adjourned until July 11, 2019 at 8:00 am Eastern Time. Less than a majority of the |
|
| July 12, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2019 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001‑37350 36‑4528166 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2019 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Nevada 001‑37350 36‑4528166 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| June 21, 2019 |
NVIV / InVivo Therapeutics Holdings Corp POS AM - - POS AM Table of Contents As filed with the Securities and Exchange Commission on June 21, 2019 Registration No. |
|
| June 14, 2019 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2019 InVivo Therapeutics Holdings Corp. (Exact Name of Registrant as Specified in Charter) Delaware 001‑37350 36‑4528166 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 14, 2019 |
Exhibit 99.1 InVivo Therapeutics Announces Adjournment of Annual Meeting Scheduled to Reconvene on July 2, 2019 - Company urgently encourages stockholders to vote - CAMBRIDGE, Mass. (June 14, 2019) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that its 2019 Annual Meeting of Stockholders, scheduled for June 11, 2019, was convened and adjourned without any business being condu |
|
| June 14, 2019 |
NVIV / InVivo Therapeutics Holdings Corp DEFA14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| June 5, 2019 |
NVIV / InVivo Therapeutics Holdings Corp DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| June 5, 2019 |
NVIV / InVivo Therapeutics Holdings Corp DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 17, 2019 |
NVIV / InVivo Therapeutics Holdings Corp POS AM POS AM As filed with the Securities and Exchange Commission on May 17, 2019 Registration No. |
|
| May 10, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| April 25, 2019 |
proxy statement for the 2019 Annual Meeting of Stockholders, filed on April 25, 2019 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 15, 2019 |
NVIV / InVivo Therapeutics Holdings Corp PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 1, 2019 |
NVIV / InVivo Therapeutics Holdings Corp S-8 As filed with the Securities and Exchange Commission on April 1, 2019 Registration No. |
|
| April 1, 2019 |
Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed on April 1, 2019 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001‑37350 INVIVO THER |
|
| February 14, 2019 |
NVIV / InVivo Therapeutics Holdings Corp / CVI Investments, Inc. - SC 13G/A Passive Investment CUSIP No: 46186M407 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* InVivo Therapeutics Holdings Corp. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 46186M40 |
|
| February 14, 2019 |
NVIV / InVivo Therapeutics Holdings Corp / Frigate Ventures LP - SC 13G/A Passive Investment SC 13G/A 1 d683579dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A (Rule 13d-102) (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) InVivo Therapeutics Holdings Corp. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) |
|
| January 14, 2019 |
Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 8 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchase shares of Common Stock |
|
| January 14, 2019 |
Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 8 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchase shares of Common Stock |
|
| January 14, 2019 |
INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333‑222738 PROSPECTUS SUPPLEMENT NO. 15 (TO PROSPECTUS DATED FEBRUARY 12, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock This prospectus supplement No. 15 supplements and amends the prospectus dated February 12, 2018, as supplemented by prospectus supplement No. 1 dated March 13, 2018, prospectus suppleme |
|
| January 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 14, 2019 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001‑37350 36‑4528166 (State or Other (Commission File Number) (IRS Employe |
|
| January 14, 2019 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is made between InVivo Therapeutics Holdings Corp. (the “Company”) a corporation duly organized and validly existing under the laws of the State of Nevada having a business address of One Kendall Square, Building 1400 East, Floor 4, Cambridge, MA 02139, and Richard Christopher (the “Executive”). WITNESSETH THAT: WHEREAS, |
|
| January 14, 2019 |
Exhibit 10.2 INVIVO THERAPEUTICS HOLDINGS CORP. NONSTATUTORY STOCK OPTION AGREEMENT InVivo Therapeutics Holdings Corp. (the “Company”) hereby grants the following stock option. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Richard Christopher Date of this option grant: January 14, 2019 Number of shares of the Company’s Common |
|
| January 4, 2019 |
Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 7 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchase shares of Common Stock |
|
| January 4, 2019 |
INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333‑222738 PROSPECTUS SUPPLEMENT NO. 14 (TO PROSPECTUS DATED FEBRUARY 12, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock This prospectus supplement No. 14 supplements and amends the prospectus dated February 12, 2018, as supplemented by prospectus supplement No. 1 dated March 13, 2018, prospectus suppleme |
|
| January 4, 2019 |
424B3 1 f424b3.htm 424B3 Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 7 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchas |
|
| January 4, 2019 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 4, 2019 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employer |
|
| December 14, 2018 |
Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 6 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchase shares of Common Stock |
|
| December 14, 2018 |
Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 6 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchase shares of Common Stock |
|
| December 14, 2018 |
INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333‑222738 PROSPECTUS SUPPLEMENT NO. 13 (TO PROSPECTUS DATED FEBRUARY 12, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock This prospectus supplement No. 13 supplements and amends the prospectus dated February 12, 2018, as supplemented by prospectus supplement No. 1 dated March 13, 2018, prospectus suppleme |
|
| December 14, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 10, 2018 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001‑37350 36‑4528166 (State or Other (Commission File Number) (IRS Employ |
|
| November 16, 2018 |
INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333‑222738 PROSPECTUS SUPPLEMENT NO. 12 (TO PROSPECTUS DATED FEBRUARY 12, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock This prospectus supplement No. 12 supplements and amends the prospectus dated February 12, 2018, as supplemented by prospectus supplement No. 1 dated March 13, 2018, prospectus suppleme |
|
| November 16, 2018 |
Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 5 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchase shares of Common Stock |
|
| November 16, 2018 |
Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 5 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchase shares of Common Stock |
|
| November 16, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 13, 2018 Date of Report (Date of Earliest Event Reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employ |
|
| November 13, 2018 |
INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333‑222738 PROSPECTUS SUPPLEMENT NO. 11 (TO PROSPECTUS DATED FEBRUARY 12, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock This prospectus supplement No. 11 supplements and amends the prospectus dated February 12, 2018, as supplemented by prospectus supplement No. 1 dated March 13, 2018, prospectus suppleme |
|
| November 13, 2018 |
Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 4 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchase shares of Common Stock |
|
| November 13, 2018 |
Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 4 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchase shares of Common Stock |
|
| November 13, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2018 Date of Report (Date of Earliest Event Reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001‑37350 36‑4528166 (State or Other (Commission File Number) (IRS Employe |
|
| November 8, 2018 |
Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 3 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchase shares of Common Stock |
|
| November 8, 2018 |
INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration Statement No. 333‑222738 PROSPECTUS SUPPLEMENT NO. 10 (TO PROSPECTUS DATED FEBRUARY 12, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock This prospectus supplement No. 10 supplements and amends the prospectus dated February 12, 2018, as supplemented by prospectus supplement No. 1 dated March 13, 2018, p |
|
| November 8, 2018 |
Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 3 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchase shares of Common Stock |
|
| November 8, 2018 |
NVIV / InVivo Therapeutics Holdings Corp 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . |
|
| October 5, 2018 |
Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 2 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchase shares of Common Stock |
|
| October 5, 2018 |
INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333‑222738 PROSPECTUS SUPPLEMENT NO. 9 (TO PROSPECTUS DATED FEBRUARY 12, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock This prospectus supplement No. 9 supplements and amends the prospectus dated February 12, 2018, as supplemented by prospectus supplement No. 1 dated March 13, 2018, prospectus supplement |
|
| October 5, 2018 |
Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 2 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchase shares of Common Stock |
|
| October 5, 2018 |
EX-10.1 2 ex-10d1.htm EX-10.1 Exhibit 10.1 Amendment to the Employment Agreement This Amendment to the Employment Agreement (the “Amendment”) is entered into by and between InVivo Therapeutics Holdings Corp. (the “Company”) and Richard Toselli, M.D. (the “Executive”) and shall become effective as of October 1, 2018 (the “Effective Date”). WHEREAS, the Company and Executive are parties to an Employ |
|
| October 5, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 1, 2018 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Number) (IRS Employer |
|
| September 28, 2018 |
Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 1 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchase shares of Common Stock |
|
| September 28, 2018 |
Filed pursuant to Rule 424(b)(3) Registration Statement Nos. 333‑224424 and 333‑225768 PROSPECTUS SUPPLEMENT NO. 1 (TO PROSPECTUS DATED JUNE 20, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. 388,403 shares of Common Stock and 388,403 Warrants to purchase shares of Common Stock and 6,242,811 Pre-Funded Warrants to purchase shares of Common Stock and 6,242,811 Warrants to purchase shares of Common Stock |
|
| September 28, 2018 |
INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration Statement No. 333‑222738 PROSPECTUS SUPPLEMENT NO. 8 (TO PROSPECTUS DATED FEBRUARY 12, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock This prospectus supplement No. 8 supplements and amends the prospectus dated February 12, 2018, as supplemented by prospectus supplement No. 1 dated March 13, 2018, prospectus supplement |
|
| September 28, 2018 |
Exhibit 10.2 SERIES A COMMON STOCK PURCHASE WARRANT INVIVO THERAPEUTICS HOLDINGS CORP. Warrant Shares: 7,621,211 Initial Exercise Date: June 25, 2018 CUSIP: 46186M 126 ISIN: US46186M1264 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and t |
|
| September 28, 2018 |
8-K 1 f8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 27, 2018 Date of Report (Date of earliest event reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File |
|
| September 28, 2018 |
SERIES B PRE-FUNDED COMMON STOCK PURCHASE WARRANT INVIVO THERAPEUTICS HOLDINGS CORP. Exhibit 10.3 SERIES B PRE-FUNDED COMMON STOCK PURCHASE WARRANT INVIVO THERAPEUTICS HOLDINGS CORP. Warrant Shares: 6,242,811 Initial Exercise Date: June 25, 2018 CUSIP: 46186M 134 ISIN: US46186M1348 THIS SERIES B PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, CEDE & CO. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitat |
|
| September 28, 2018 |
Exhibit 10.1 Amendment to Warrant Agency Agreement and Warrants This Amendment, dated September 27, 2018 (“Amendment”), is entered into by and between InVivo Therapeutics Holdings Corp., a Nevada corporation (the “Company”), and Continental Stock Transfer & Trust Company as Warrant Agent (the “Warrant Agent”), and amends that certain Warrant Agency Agreement, dated as of June 25, 2018 (the “Warran |
|
| September 28, 2018 |
Exhibit 99.1 CONTACT: Heather Hamel (617) 863-5530 Investor Relations [email protected] InVivo Therapeutics Announces Presentation at the Ladenburg Thalmann 2018 Healthcare Conference and Provides Business Update CAMBRIDGE, Mass. (Sept. 28, 2018) – InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that Richard Toselli, M.D., President and Chief Executive Officer, will prese |
|
| August 21, 2018 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 f8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 15, 2018 Date of Report (Date of Earliest Event Reported) INVIVO THERAPEUTICS HOLDINGS CORP. (Exact Name of Registrant as Specified in Charter) Nevada 001-37350 36-4528166 (State or Other (Commission File Nu |
|
| August 7, 2018 |
INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-222738 PROSPECTUS SUPPLEMENT NO. 7 (TO PROSPECTUS DATED FEBRUARY 12, 2018) INVIVO THERAPEUTICS HOLDINGS CORP. Up to 10,700,000 shares of Common Stock This prospectus supplement No. 7 supplements and amends the prospectus dated February 12, 2018, as supplemented by prospectus supplement No. 1 dated March 13, 2018, pro |
